BioClinica releases new Trident IWR solution

BioClinica^®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced a new release of Trident IWR, the latest addition to its best-in-class suite of eClinical applications. BioClinica will highlight Trident and other new product offerings at booth #1417, providing demonstrations of BioClinica's Integrated Clinical Trial Solutions, including:

• Trident IWR Randomization to Express EDC
• Express CRF Status to OnPoint CTMS and Clinical Payment Manager
• Trident + Optimizer 360 Degree Clinical Supplies Forecasting and Management
• Unified Reporting
• Customer Portals
• Microsoft Office Interoperability
• Ad Hoc Reporting

BioClinica will also participate in a clinical solutions showcase for the Microsoft platform, where they will demonstrate BioClinica's open, standards-based architecture within the Microsoft Connected Life Sciences Framework guidance.

"Fewer drugs make it to market each year, yet many pharmaceutical companies continue to use the same development processes and procedures within an antiquated architecture," said Michael Naimoli, Worldwide Managing Director, Life Sciences, Microsoft. "Microsoft and several partners, including BioClinica, worked together to develop a standard approach to information architecture across the industry that could enable companies to unlock valuable data, such as information that could lead to new therapies, and share that data among partners, customers and even regulatory agencies."

To see the benefits of this solution, please visit Microsoft at booth #1111 and BioClinica at booth #1417. The DIA 2011 Annual Meeting is being held in Chicago from June 20 - 23, with exhibits opened June 20 - 22.

Trident IWR provides clinical operations personnel an intuitive way to directly set up, monitor, and maintain randomization and supplies for their clinical trials. Trident's powerful parameter-driven study set-up eliminates programming for each new clinical trial and it configures both web and voice at the same time. This leads to greater efficiencies in starting new studies in a less costly manner and in a fraction of the time than other alternatives. This new release enhances Trident's capabilities for features such as managing temperature sensitive supplies and advanced supply pooling.

"Trident is truly changing the IWR landscape," said Mark Weinstein, CEO of BioClinica. "Clinical studies using Trident are typically developed and deployed within weeks. The combination of set-up speed and support for configuring even complex designs allows sponsors to make mid-study or last minute changes without affecting study timelines. This solution is literally changing what people can do with IWR/ IVR."